Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 210.61$. Average daily volumn in 3 months 1.22M. Market cap 38.75B

Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD
Lastest price : 267.00$. Total volume : 3.75M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Biogen Inc. (BIIB)
Last Price

Previous Close264.28
Day Range257.02-271.30
Bid267.01 x 1.2k
Ask266.89 x 800
Average Volume1.22M
Market Cap38.75B
52 Week Range187.16-290.76
Trailing P/E19.36
Foward P/E16.98
Dividend (Yield %)N/A
Ex-Dividend DateN/A

Financial Details

According to Biogen Inc.'s financial reports the company's revenue in 2021 were 10.98B an decrease(-23.08%) over the years 2020 revenue that were of 13.44B. In 2021 the company's total earnings were 1.56B while total earnings in 2020 were 4B(-75%).

Loading ...


Market Cap:
Total Assets:
Total Cash:

News about "Biogen Inc."


Biogen shares soar on landmark Alzheimer's data, lift rivals

Source from : Reuters - 2 days ago

Biogen Inc was set to add more than $10 billion to its market capitalization on Wednesday, as a surprise trial success of the experimental Alzheimer's drug it developed with Eisai was hailed as an ...See details»


Five questions around Biogen in wake of the new Alzheimer's drug data

Source from : The Business Journals - 2 days ago

Biogen has spent much of the year shedding assets following the disastrous rollout of its first Alzheimer's disease drug. Will its new Alzheimer's drug turn things around and allow the drugmaker to ...See details»


Are Investors Undervaluing Biogen Inc. (NASDAQ:BIIB) By 40%?

Source from : YAHOO!Finance - 2 days ago

In this article we are going to estimate the intrinsic value of Biogen Inc. (NASDAQ:BIIB) by taking the forecast future cash flows of the company and discounting them back to today's value. Our ...See details»


Biogen (NASDAQ:BIIB) Price Target Increased to $300.00 by Analysts at Oppenheimer

Source from : Defense World - 1 days ago

Biogen (NASDAQ:BIIB โ€“ Get Rating) had its price objective increased by Oppenheimer from $230.00 to $300.00 in a research report sent to investors on Thursday morning, The Fly reports. A number of ...See details»


Biogen Inc.'s (NASDAQ:BIIB) latest 6.5% decline adds to one-year losses, institutional investors may consider drastic measures

Source from : Nasdaq - 3 days ago

If you want to know who really controls Biogen Inc. (NASDAQ:BIIB), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with ...See details»

Biogen: EMA Accepts Application for RoActemra Biosimilar >BIIB

Source from : MarketWatch - 1 days ago

By Colin Kellaher Biogen Inc. on Friday said the European Medicines Agency has accepted its application seeking approval of BIIB800, a proposed biosimilar ...See details»


Pharmaceutical company Biogen agrees to pay $900 million to settle kickback claims

Source from : Washington Times - 3 days ago

Pharmaceutical company Biogen Inc. has agreed to pay $900 million to settle allegations that it paid kickbacks to doctors to recommend its multiple sclerosis drugs, causing false submission claims to ...See details»


Biogen Inc. Agrees to Pay $900 Million to Settle Allegations Related to Improper Physician Payments

Source from : The National Law Review - 5 days ago

Pharmaceutical company Biogen Inc. (Biogen), based in Cambridge, Massachusetts, has agreed to pay $900 million to resolve allegations that it caused the submission of false claims to Medicare and Medi ...See details»


7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Source from : Business Insider - 2 days ago

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimerโ€™s drug with Japanese partner Eisai showed promising results. RBC Capital Marke ...See details»


Biogen Rally Adds $11 Billion in Value on Alzheimerโ€™s Win

Source from : Yahoo - 2 days ago

Biogen Inc. rose the most since November 2020 after a key clinical trial with its partner Eisai Co. showed the therapy lecanemab slowed the progression of Alzheimerโ€™s disease.Most Read from ...See details»


Biogen finalizes $900 mln drug kickback settlement, U.S. says

Source from : Reuters - 4 days ago

Biogen Inc has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs, the U.S. Department ...See details»


Western Wealth Management LLC Sells 375 Shares of Biogen Inc. (NASDAQ:BIIB)

Source from : Defense World - 3 days ago

Western Wealth Management LLC reduced its stake in Biogen Inc. (NASDAQ:BIIB โ€“ Get Rating) by 8.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and ...See details»


What Weโ€™re Reading: Biogen Agrees to Settlement; Fertility Preservation for Patients With Cancer; Supreme Court Medicaid Case

Source from : The American Journal of Managed Care - 3 days ago

Biogen Inc agreed to pay $900 million to settle allegations about improper physician payments; the American Cancer Society warns that fertility preservation for patients with cancer is at risk after ...See details»


Alzheimer's patient advocates hopeful โ€” but cautiousโ€” on Biogen news

Source from : The Business Journals - 2 days ago

Positive data on Biogen' Alzheimer's drug helped restore investor confidence in the Cambridge drugmaker. But patient advocates are waiting for the full study results. But patient advocates are still ...See details»